Skip to main content
. 2018 Jul 2;16(3):3690–3698. doi: 10.3892/ol.2018.9055

Figure 1.

Figure 1.

TACE combined with sorafenib. TS significantly reduced the diameter of tumor-associated arteries, including the (A) hepatic artery, (B) proper hepatic artery and (C) hepatic branches. *P<0.05. TS did not change the diameter of the non-tumor associated arteries, including the (D) splenic artery, (E) gastroduodenal artery and (F) left gastric artery. P>0.05. G, K, H, L, I, M, J and N represent the same patient prior and subsequent to adminstration of sorafenib respectively. G, H, I and J are images collected in the first TACE procedure; K, L, M and N are images collected in the second TACE procedure. (G) Arrow from left to right indicates the proper hepatic, hepatic and splenic arteries. (H) Arrow indicates left gastric artery. (I) Arrow from left to right indicates the hepatic artery branches and gastroduodenal artery. (J) Arrow from left to right indicates the hepatic artery branches and gastroduodenal artery. (K) Arrow from left to right indicates the proper hepatic, hepatic and splenic arteries. (L) Arrow indicates left gastric artery. (M) Arrow from left to right indicates the hepatic artery branches and gastroduodenal artery. (N) Arrow from left to right indicates hepatic artery branches and gastroduodenal artery. TACE, transarterial chemoembolization; TS group, TACE combined with sorafenib. The magnification for all images in Figure 1 is 1:4.